carmot-therapeutics.usHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $594.61MM
Carmot Therapeutics is focused on the discovery and development of disease-modifying therapies for patients living with metabolic diseases and cancer. Carmot applies Chemotype Evolution (CE), a pioneering drug discovery platform, in combination with unique biological expertise to identify innovative and superior therapeutics.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/25/2023 | Series E | $150MM | $xx.xx | $696.68MM | 5am Ventures, Deep Track Capital, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, Ra Capital Management, Tcgx, The Column Group, Venrock Healthcare Capital Partners, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
6,519,392
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
5am Ventures, Deep Track Capital, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, Ra Capital Management, Tcgx, The Column Group, Venrock Healthcare Capital Partners, Willett Advisors
|
||||||
08/26/2022 | Series D-1 | $30.23MM | $xx.xx | $464.88MM | Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
1,853,391
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
|
||||||
08/26/2022 | Series D | $130.44MM | $xx.xx | $464.88MM | Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors | |
Price per Share
$xx.xx
Shares Outstanding
6,798,176
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
|
||||||
09/30/2020 | Series C | $46.88MM | $xx.xx | $179.66MM | Amgen Ventures, Horizons Ventures, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
3,215,335
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Horizons Ventures, The Column Group
|
||||||
01/17/2018 | Series B | $12.59MM | $xx.xx | $57.39MM | Horizons Ventures, Jerome Dahan, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
1,977,878
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Horizons Ventures, Jerome Dahan, The Column Group
|
||||||
04/07/2010 | Series A | $2.16MM | $xx.xx | $4.8MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,431,745
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|